Michael A. Scarpone and Daniel Kuebler released a new comparative analysis on Marrow Cellution™ vs. the EMCYTE® BMC System.
Main conclusion points in this study are:
- CFU-f and CD34+ counts were significantly higher with the Marrow Cellution™ aspiration system than in the final (concentrated) EMCYTE® BMC product.
- The Marrow Cellution™ aspirate had less contaminating peripheral blood compared to the EMCYTE® BMC.
- Marrow Cellution™ required less preparation time.
Read the complete document: Scarpone MA, Kuebler D. Comparative Analysis of Marrow Cellution™ and Emcyte® BMC System. White Paper June 2017.
The Marrow Cellution™ System is designed to minimize and eliminate the restrictive limitations associated with “point of care” processing systems which employ inefficient traditional aspiration trocar technology and are regulated as drugs “Advanced Therapies Medicinal Products (ATMP)”. Marrow Cellution™ is a minimally invasive bone/cell enriched autograft access and retrieval system, which does not require additional manipulation or processing, it never leaves the sterile field and provides rich autograft without associated morbidity.
Visit our Marrow Cellution product page